The influence of oxalate decarboxylase on the urinary oxalate excretion in swine model of nephrocalcinosis induced by hydroxyproline
DOI:
https://doi.org/10.15584/ejcem.2017.3.4Keywords:
Nephrocalcinosis, Oxalate decarboxylase, Hydroxyproline, Pig modelAbstract
Introduction. Kidney stone formation may be a result of increased urinary oxalate supersaturation.
Material and methods. Eighteen pigs were randomly divided into: Control group, where standard cereal-based feed was supplemented with 4% HP only, Prevention group, where treatment with OxDc slurry started at the end of the adaptation period when pigs were switched to 4% HP diet, Reduction group, where the treatment with OxDc lyo powder started after pigs were already on a 4% HP diet for 6 days.
Results. OxDc slurry prevented oxalate excretion in urine. The reduction effect of OxDc lyo feed addition was generally visible during the first two days of the therapy (p<0.05). Both dietary intake of 4% HP and OxDc preparations did not influence weight gain, water or feed intake, urine excretion and creatinine clearance.
Conclusion. The capacity of OxDc in preventing induced hyperoxaluria was moderate. Most probably, this is due to the incoherent response of animals to the HP enriched diet dependent on their gut pH, since optimum pH for OxDc is around 5-6. A higher pH essentially reduces the activity of OxDc. The capacity of OxDc in reversing the hyperoxaluria induced by a HP enriched diet was significant during the first 2 days after introducing OxDc to the diet.
Downloads
References
Khan SR. Nephrocalcinosis in animal models with and without stones. Urol Res. 2010;38(6):429-438.
Hope B, Kemper MJ, Bökenkamp A, et al. Plasma oxalate calcium supersaturation in children with primary hyperoxaluria and end stage renal failure. Kidney Int. 1999;56(1):268-274.
Knight J, Jiang J, Assimos DG, Holmes RP. Hydroxyproline ingestion and urinary oxalate and glycolate excretion. Kidney Int. 2006;70(11):1929-1934.
Mendel NS, Henderson JR, Hung LY, Wille D, Wiessner JH. A porcine model of calcium oxalate kidney stone disease. J Urol. 2004;171(3):1301-1303.
Kaplon DM, Penniston KL, Darriet C, Crenshaw TD, Nakada SY. Hydroxyproline-induced hyperoxaluria using acidified and traditional diets in the porcine model. J Endourol. 2010;24(3):355-359.
Grujic D, Salido EC, Shenoy BC, et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol. 2009;29(2):86-93.
Hatch M, Freel RW. Alterations in intestinal transport of oxalate in disease states. Scanning Microsc. 1995;9(4):1121-1126.
Mandel NS, Henderson JR, Hung LY, Wille D, Wiessner JH. A porcine model of calcium oxalate kidney stone disease. J Urol. 2004;171:1301–1303.
Khan SR, Glenton PA, Byer KJ. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: Experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int. 2006;70:914–923.
Goncharova K, Filip R, Świeboda P, et al. Model development of hydroxyproline induced hyperoxaluria in young growing pigs. Eur J Clin Exp Med. 2017;15(1):6–11.
Bushinsky DA, Asplin JR, Grynpas MD, et al. Calcium oxalate stone formation in genetic hypercalciuric stone forming rats. Kidney Int. 2002;61:975. of patients with Rheumatoid Arthritis. Ann Acad Med Bialost. 2005;50:170-173.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
